Wednesday , November 22 2017
Home / 2016 / October

Monthly Archives: October 2016

Roche Licenses its PI3K Pathway Brain Cancer Drug to Novogen

SYDNEY, Oct. 30, 2016 /PRNewswire/ — Australian oncology-focused biotechnology company, Novogen Ltd (ASX: NRT; NASDAQ: NVGN) today announced that it has entered into a worldwide licensing agreement with Genentech, a member of the Roche Group, to develop and commercialize GDC-0084, a small molecule inhibitor of the phosphoinositide-3-kinase (PI3K) pathway. The …

Read More »

FDA Approves New Device for Prevention of Recurrent Strokes in Certain Patients

ST. PAUL, Minn.–(BUSINESS WIRE)–St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced the U.S. Food and Drug Administration (FDA) approval and launch of the AMPLATZER™ PFO Occluder to help reduce the risk of recurrent ischemic strokes in patients diagnosed with a patent foramen ovale (PFO) – a …

Read More »

Study Finds Incidence of Anal Cancer Rising Worldwide

October 28, 2016– A new American Cancer Society study finds that incidence of anal cancer has been increasing in women or in both men and women in 13 of 18 countries studied, particularly in the Americas, Northern and Western Europe, and Australia. The authors say population-based preventive measures, including human …

Read More »

Therapix Develops Formulations for a Tablet for Sublingual Administration of THC for Pharmaceutical Use

TEL AVIV, Israel, October 31, 2016 /PRNewswire/ — Therapix Biosciences, (OTCQB: THXBY) (TASE: THXBY.TA) the pharma company specializing in the development and commercialization of cannabinoid-based drugs, announced the successfully completion of the development phase of a unique formulation of a tablet for sublingual administration for pharmaceutical use. The tablet is …

Read More »

Cancer Moonshot 2020 Announces Launch of Nation’s Largest Pediatric Brain Tumor Atlas

BOSTON–(BUSINESS WIRE)–NantHealth, Inc.(Nasdaq: NH), a leading next-generation, evidence-based, personalized healthcare company, the Chan Soon-Shiong Institute of Molecular Medicine and the collaborators of the Pediatric Cancer MoonShot 2020 today announced that they are embarking on one of the world’s most ambitious pediatric sequencing discovery projects to date. This initiative will focus …

Read More »

FDA Rejects Sanofi and Regeneron’s Rheumatoid Arthritis Drug due to Manufacturing Concerns

Paris and Tarrytown, N.Y. – October 28, 2016 – Sanofi and Regeneron Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) regarding the Biologics License Applications (BLA) for sarilumab, an investigational interleukin-6 receptor (IL-6R) antibody for the treatment of adult patients with …

Read More »

Eisai Initiates Two Phase 3 Trials with Fycompa in Children with Epilepsy

WOODCLIFF LAKE, N.J., Oct. 28, 2016 /PRNewswire/ — Eisai Inc. announced today the initiation of two multi-center, global Phase 3 clinical trials assessing FYCOMPA® (perampanel) CIII in two different patient populations: patients age 2 years and above with inadequately controlled seizures associated with Lennox-Gastaut Syndrome (LGS) (Study 338), a rare …

Read More »

Allergan Expands Gastroenterology Pipeline through Acquisition of Motus Therapeutics

DUBLIN and BOSTON, Oct. 27, 2016 /PRNewswire/ — Allergan plc. (NYSE: AGN), a leading global pharmaceutical company and Rhythm Holding Company, LLC, which owns Motus Therapeutics, Inc. a biopharmaceutical company developing peptide therapeutics for the treatment of gastrointestinal (GI) disorders, announced today the top line results of a Phase 2b clinical …

Read More »

Promise of Better Targeted Treatments Now Possible in Children’s Brain Cancer

SALT LAKE CITY — More than 4,000 children and teens are diagnosed with brain cancer each year and the disease kills more children than any other cancer. Writing this week in the journal Cell Reports, researchers at Huntsman Cancer Institute (HCI) at the University of Utah report they have identified …

Read More »

Astellas to Acquire Ganymed Pharmaceuticals in Potential $1.4 Billion Deal

TOKYO and MAINZ, Germany, Oct. 28, 2016 /PRNewswire/ — Astellas Pharma Inc. (TSE: 4503, President and CEO: Yoshihiko Hatanaka, “Astellas”) and Ganymed Pharmaceuticals AG (CEO; Özlem Türeci, “Ganymed”), a biopharmaceutical company located in Mainz, Germany which focuses on the development of antibodies against cancer, announced today that Astellas and Ganymed’s …

Read More »